Serina Therapeutics (SER) Income from Non-Controlling Interests (2018 - 2025)
Serina Therapeutics (SER) posted Income from Non-Controlling Interests of -$10000.0 for Q3 2025, up 28.57% sequentially from -$14000.0 in Q2 2025, and up 62.96% YoY from -$6136.4 in Q3 2024.
Serina Therapeutics (SER) Income from Non-Controlling Interests (2018 - 2025) Analysis & Trends
Serina Therapeutics has reported Income from Non-Controlling Interests for 8 years, with the latest figure at -$10000.0 in Q3 2025.
- Quarterly Income from Non-Controlling Interests rose 62.96% year-over-year to -$10000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$33000.0 (up 50.0% YoY) and the FY2025 annual result came in at -$33000.0, up 50.0% from the prior year.
- Income from Non-Controlling Interests grew to -$10000.0 in Q3 2025 per SER's latest filing, from -$14000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $4000.0 in Q4 2021 and troughed at -$58000.0 in Q4 2022.
- A 5-year average of -$13846.2 and a median of -$10000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2021 and 2022: Income from Non-Controlling Interests soared 140.0% in 2021, then plunged 1550.0% in 2022.
- Over 5 years, Income from Non-Controlling Interests stood at $4000.0 in 2021, then slumped by 1550.0% to -$58000.0 in 2022, then surged by 82.76% to -$10000.0 in 2023, then slipped by 20.0% to -$12000.0 in 2024, then rose by 16.67% to -$10000.0 in 2025.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$10000.0, -$14000.0, and -$9000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Dec 31, 2024 | -12,000.00 |
| Sep 30, 2024 | -27,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Jun 30, 2023 | -10,000.00 |
| Mar 31, 2023 | -8,000.00 |
| Dec 31, 2022 | -58,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Mar 31, 2021 | -7,000.00 |
| Dec 31, 2020 | -10,000.00 |
| Sep 30, 2020 | -20,000.00 |
| Jun 30, 2020 | -41,000.00 |
| Mar 31, 2020 | -35,000.00 |
| Dec 31, 2019 | -30,000.00 |
| Sep 30, 2019 | -56,000.00 |
| Jun 30, 2019 | -66,000.00 |